cresilon

CHG Cresilon Hemostatic Gel Logo

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology

NEW YORK — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced today it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for its proprietary hemostatic gel technology. This follows Cresilon’s successful launch of VETIGEL®, its revolutionary hemostatic gel for the animal health market. …

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology Read More »

Two engineers in Cresilon's GMP biomanufacturing facility

Brooklyn Heights native’s company Cresilon creates gel to stop bleeding

By News 12 Staff Oct 28, 2021, 7:40amUpdated on: Oct 28, 2021, 7:40am Not many college freshmen start a business as soon as they get to school. However, Brooklyn Heights’ Joe Landolina had other plans in mind when starting his company Cresilon Inc. at NYU in 2010. Eleven years later, the company has a product that …

Brooklyn Heights native’s company Cresilon creates gel to stop bleeding Read More »

Cresilon's GMP manufacturing facility in Brooklyn, NY

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel

NEW YORK, April 8, 2021 – Cresilon, Inc., the Brooklyn-based biotechnology company, announced today the successful close of its Series A-3 financing, totaling $38.5 million. This financing is expected to allow the company to aggressively accelerate its global growth plan and expand the rollout of VETIGEL®, its revolutionary hemostatic gel for the animal health market. It …

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel Read More »